Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst,Christoph Plöger,Michael Gregor,Raymonde Busch,Elisabeth Lange,Stephan Stilgenbauer,Anna Maria Fink,Christian Maurer,Wolfram Klapper,Kirsten Fischer,Michael Kneba,Rudolf Schlag,Michael Hallek,Sebastian Böttcher,Ursula Vehling-Kaiser,Torben Plesner,Martin Soekler,Hartmut Döhner,H Köppler ,Marek Trněný ,Karl Kreuzer ,Michael Kiehl ,Clemens‐Martin Wendtner ,Georg Köchling ,Gabòr Kovàcs

doi:10.1182/blood.v124.21.19.19

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, Christoph Plöger + Show 23 more

Open Access

https://doi.org/10.1182/blood.v124.21.19.19

Copy DOI

#Research Funding #FCR Arm + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Full Text